Denali Therapeutics Inc. is a biotechnology company focused on developing therapeutics for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The company specializes in discovering new drug candidates that can effectively cross the blood-brain barrier and target biological pathways associated with the progression of these diseases. Denali utilizes advanced technologies, including Blood-Brain Barrier Penetration, which allows for targeted delivery of drugs directly to the central nervous system, enhancing the efficacy of treatments.